Showing 2341-2350 of 4946 results for "".
- FDA-Approved Label Update: Cosentyx Inhibits Progression of Joint Structural Damage in PsAhttps://practicaldermatology.com/news/fda-approved-label-update-cosentyx-inhibits-progression-of-joint-structural-damage-in-psa/2457718/The US FDA has approved a label update for Cosentyx® (secukinumab) from Novartis, including data that show the treatment significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA). The data will be a
- Modern Aesthetics® Set to Launch New Tweet Chat Series-- #RealDealAestheticshttps://practicaldermatology.com/news/modern-aesthetics-set-to-launch-new-tweet-chat-series-realdealaesthetics/2457720/Practical Dermatology’s sister publication, Modern Aesthetics® magazine, is launching a new Tweet chat series --#RealDealAesthetics -- featuring New York City dermatologist Gary Goldenberg, MD and Charleston, SC dermatologist Todd E. Schlesinger, MD. The f
- Valeant: FDA Issues Complete Response Letter for Duobriihttps://practicaldermatology.com/news/valeant-fda-issues-complete-response-letter-for-duobrii/2457723/Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. has received a Complete Response Letter (CRL) from the US FDA
- eRelevance Launches Suite of Services to Support Lead Conversionhttps://practicaldermatology.com/news/erelevance-launches-suite-of-services-to-support-lead-conversion/2457726/eRelevance Corporation has launched a suite of tech-powered services to help
- Restoration Robotics Launches Continuing Education Master Class for ARTAS Systemhttps://practicaldermatology.com/news/restoration-robotics-launches-continuing-education-master-class-for-artas-system/2457729/Restoration Robotics, Inc. is launching a continuing education Master Class Series for its ARTAS® Robotic Hair Restoration System to train physicians on best practices and the most up-to-date techniques for the technology. The Master Class Series will enable users to provide exceptional
- Luma Therapeutics Launches Novel illuvinate Phototherapy Systemhttps://practicaldermatology.com/news/luma-therapeutics-launches-novel-illuvinate-phototherapy-system/2457736/Luma Therapeutics has launched illuvinate as an innovative and modern twist on the Goeckerman regimen. By combining a narrowband UVB LED light with patented hydrogels containing coal tar micro-globules, illuvinate increases the skin's hydration, decreases inflammation, and suppresses overacti
- One In Two Latina Influencers Favor Complementing Diet and Exercise with Non-Surgical Body Contouringhttps://practicaldermatology.com/news/one-in-two-latina-influencers-favor-complementing-diet-and-exercise-with-non-surgical-body-contouring/2457742/More than 50 percent of Latina Influencers think that non-surgical body contouring works well with diet and exercise, according to an Allergan-sponsored survey. The survey results were part of a panel discussion with Vivian Bucay, MD a San Antonio, Texas dermatologist; Gia Fey, Curveygirl
- Skin Cancer Survey Spotlights Frustration with Perceptions of "Less Serious" Conditionhttps://practicaldermatology.com/news/skin-cancer-survey-spotlights-frustration-with-perceptions-of-less-serious-condition/2457743/People living with skin cancer struggle with perceptions that their condition is less serious than other types of cancer despite significant physical and emotional impact, according to Skin Cancer In America 2018, a national survey by Health Union, LLC of people diagnosed with the condition.
- Severe AD Linked to CV Risk in Large Trialhttps://practicaldermatology.com/news/severe-ad-linked-to-cv-risk-in-large-trial/2457748/Eczema now joins the list of inflammatory conditions linked to cardiovascular risk. British researchers report that individuals with severe eczema may be at greater risk for heart attack, stroke and atrial fibrillation. Their study appears in the
- Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosishttps://practicaldermatology.com/news/rapamycin-lotion-reduces-facial-tumors-caused-by-tuberous/2457750/Rapamycin lotion significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with tuberous sclerosis complex (TSC), researchers from The University of Texas Health Science Center at Houston (UTHealth) report. Findings of the multicenter, international stud